Rathbones Group PLC Acquires 27,590 Shares of Zoetis Inc. $ZTS

Rathbones Group PLC boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 5.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 532,064 shares of the company’s stock after acquiring an additional 27,590 shares during the quarter. Rathbones Group PLC owned 0.12% of Zoetis worth $77,852,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. North Star Asset Management Inc. increased its holdings in Zoetis by 4.9% in the second quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock valued at $225,000 after purchasing an additional 67 shares during the period. Bank of Nova Scotia Trust Co. lifted its holdings in Zoetis by 4.6% during the 2nd quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock worth $264,000 after buying an additional 74 shares during the period. RWA Wealth Partners LLC grew its position in shares of Zoetis by 2.7% in the 2nd quarter. RWA Wealth Partners LLC now owns 2,852 shares of the company’s stock valued at $445,000 after buying an additional 76 shares during the last quarter. Summit Place Financial Advisors LLC grew its position in shares of Zoetis by 0.4% in the 3rd quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock valued at $2,834,000 after buying an additional 76 shares during the last quarter. Finally, Stokes Family Office LLC increased its stake in shares of Zoetis by 2.4% in the second quarter. Stokes Family Office LLC now owns 3,357 shares of the company’s stock valued at $524,000 after buying an additional 78 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of Zoetis stock opened at $121.54 on Friday. The business has a 50-day simple moving average of $126.06 and a 200 day simple moving average of $133.05. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.00. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm has a market capitalization of $51.31 billion, a price-to-earnings ratio of 20.19, a PEG ratio of 1.85 and a beta of 0.95.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. HSBC set a $140.00 price objective on Zoetis in a research note on Wednesday, December 10th. Morgan Stanley set a $160.00 price target on shares of Zoetis in a report on Thursday, December 18th. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. BTIG Research reiterated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Finally, Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.